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ABSTRACT
Anti-EGFR mAbs cetuximab and panitumumab are routinely used for the treatment 
of patients with KRAS-wild type metastatic colorectal cancer (mCRC). However, in 
some patients their efficacy remains modest and with no clear association between 
the EGFR protein expression determined by PharmDx™ kit, and response to anti-EGFR 
therapies. Therefore, we investigated the relative expression and predictive value 
of wild-type EGFR (wtEGFR), mutated EGFRvIII and EGFR ligand proteins in mCRC 
patients treated with cetuximab. The expression levels of wtEGFR, EGFRvIII, and EGFR 
ligand were determined by immunohistochemistry (IHC) in 60 tumour specimens 
using specific antibodies. Sections were scored according to the percentage of positive 
tumour cells, intensity and cellular location of staining, and these were associated 
with response, overall survival (OS) and progression-free survival (PFS). At cut-off 
value > 5%, wtEGFR, and EGFRvIII were present in 44%, and 41%, betacellulin (BTC) 
in 72%, followed by epigen (67%), TGFα (58%), amphiregulin (34%), EGF (31%) 
of the cases, respectively and 96% of the wtEGFR positive cases had co-expression 
of at least one ligand. We found a significant association between the expression 
of wtEGFR and poor response to cetuximab. In addition, the co-expression of wtEGFR 
with one ligand at a cut-off value of > 5% and > 10% was associated with worse 
response to cetuximab (P = 0.021, and P = 0.005 respectively). We found a 3-fold and 
5-fold increased risk of shorter OS with expression of BTC and epigen. Interestingly, 
the expression of wtEGFR and its co-expression with one or two ligands was associated 
with shorter PFS but not with OS. The relative expression of wtEGFR and its competing 
ligands, which is the target for therapeutic interventions with anti-EGFR antibodies, could 
serve as a more reliable predictive biomarker of response to therapy with anti-EGFR 
mAbs in mCRC patients and warrants further investigation in large prospective studies.
INTRODUCTION
Colorectal cancer remains one of the leading causes 
of cancer deaths worldwide [1]. In 2016, colorectal cancer 
is estimated to be the third most commonly diagnosed 
cancer (134,900) and the third leading cause of cancer 
deaths (49,190) in the USA [2], highlighting the need 
for developing more effective and less toxic therapeutic 
agents. In the last three decades, the aberrant expression 
of the epidermal growth factor receptor (EGFR) has been 
reported in a wide range of tumours including colorectal, 
head and neck and lung cancers and the EGFR is currently 
an important therapeutic target for targeted therapy with 
anti-EGFR antibodies in such patients [3]. While treatment 
with a combination of antibodies and cytotoxic drugs 
improves response rate and median time to progression in 
some colorectal cancer patients, the duration of response 
is often limited in most patients with an advanced stage 
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of the disease [3]. To date, of the anti-EGFR monoclonal 
antibodies (mAbs), only cetuximab and panitumumab 
have been approved for the treatment of patients with 
metastatic colorectal cancer (mCRC) with RAS wild-
type status [4– 8]. However, no clear association has 
been found between the expression level of the EGFR 
protein in the tumours, determined by the FDA approved 
EGFR PharmDx™ kit, or other standard anti-EGFR 
antibodies, and the response to the EGFR inhibitors 
[3, 9–12]. We have previously shown that kits such as 
the EGFR PharmDx™, does not discriminate between 
the wtEGFR and  EGFRvIII, and as such could have a 
major contribution to the lack of association between the 
expression of EGFR and response to anti-EGFR antibodies 
in such studies [13]. This is of vital importance as the 
wtEGFR protein is not only the therapeutic target for anti-
EGFR antibodies but also transmits the mitogenic action 
of competing autocrine and paracrine EGFR ligands [14]. 
In recent years, while RAS mutation has served as 
an important negative predictive biomarker for response to 
therapy with anti-EGFR mAbs in patients, not all patients 
with wild type KRAS gain benefit from therapy with anti-
EGFR mAbs [15, 16] and objective responses of up to 
44% have been reported in mCRC patients with KRAS 
mutations treated with cetuximab in other studies [17]. In 
addition, several studies of gene expression of some of the 
EGFR ligands have indicated that an increased expression 
of amphiregulin, epiregulin, TGFα may act as prognostic 
indicators and predictive biomarkers of response to 
therapy with anti-EGFR mAbs [18–25]. However, to our 
knowledge; there have been no comprehensive studies on 
the protein expression levels of wtEGFR and all EGFR 
ligands in mCRC patients and their predictive values 
for response to treatment with anti-EGFR mAbs such 
as cetuximab. Therefore, in this study, using specific 
antibodies we have investigated the expression levels 
of  wtEGFR, EGFRvIII, phosphorylated EGFR and 
all seven EGFR ligands in tumour specimens from 60 
mCRC patients with KRAS wild-type status treated with 
cetuximab and their associations with clinicopathological 
parameters, PFS and OS. 
RESULTS
Clinicopathological features
Patient clinicopathological characteristics are 
summarised in Table 1. The median patient follow-up 
time was 4 years, median OS was 2.7 years and median 
PFS was 3 months. All patients received FOLFIRI 
(irinotecan and modified de Gramont) plus cetuximab 
or FOLFOX (oxaliplatin and modified de Gramont) 
plus cetuximab therapies as first line chemotherapy.  An 
improved OS (P = 0.017) and a longer PFS was observed 
in patients with vascular invasion, which is unusual. Those 
patients with T4 cancers had a significantly shorter PFS 
(P = 0.014), compared with those cancers with a less 
advanced T stage (Table 1). 
Immunohistochemical expression of EGFR, and 
EGFR ligands
For the first time, in this study we determined the 
relative expression of EGFR using mAbs specific for the 
wild-type and EGFRvIII as well as the expression and co-
expression of all EGFR ligands. Of the 60 cases examined, 
44% and 41% were found to be positive for wtEGFR and 
EGFRvIII, respectively. The predominant staining pattern 
of wtEGFR was cytoplasmic (44%), with some cases 
having membranous staining (12%), while EGFRvIII 
expression was only cytoplasmic (Figure 1, Table 2). 
Of the EGFR ligands, BTC was the most commonly 
expressed ligand (72%), followed by epigen (67%), TGFα 
(58%), amphiregulin (34%), EGF (31%) (Figure 2A, 
Table 2). The expression of HB-EGF, epiregulin, and 
phosphorylated EGFR (1068 and 1173) were undetectable 
in tumour sections in this study. No nuclear staining was 
detected in this study. 
Co-expression of wtEGFR with any one, two, three 
or four ligands was 43%, 35%, 23% and 15% respectively 
(Table 2). In addition, one patient co-expressed wtEGFR 
with all five EGFR ligands (Figure 2B).
Expression of wtEGFR and EGFR ligands and 
their association with response to therapy and 
disease progression
A significant association was found between 
wtEGFR expression at cut-off value of > 5% positive 
tumour cells and poor response to treatment with 
cetuximab (P = 0.026) as well as disease progression 
(P = 0.002) (Table 3). Of the EGFR ligands, the expression 
of amphiregulin at a cut-off value of > 10% tumour cells 
(P = 0.013), EGF (>50%) (P = 0.045), and co-expression 
of epigen/BTC (P = 0.032) were significantly associated 
with an increased disease progression in this study (Table 
3), while BTC expression at cut-off value of > 5% was 
associated with decreased disease progression (P = 0.006). 
The co-expression of wtEGFR with one ligand at 
a cut-off value of >5% and > 10% was associated with 
worse response to cetuximab (P = 0.021, and P = 0.005 
respectively) (Table 3). This was also true in the case of 
the co-expression of wtEGFR with BTC at cut-off values 
of >10% and >20% and wtEGFR and TGFα at cut-off 
value of >10% (Table 3). Interestingly, the co-expressions 
of wtEGFR and amphiregulin, BTC, epigen, and TGFα 
were all significantly associated with a decreased disease 
progression (Table 3). A significant association was also 
found between the co-expression of wtEGFR with one 
ligand (P = 0.002), two ligands (P = 0.022) or, three 
ligands (P = 0.026) at cut-off value of >5% and disease 
progression in this study (Table 3).    
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Impact of EGFR and EGFR ligands expression 
on overall survival 
The association between the expression of wtEGFR 
and its ligands and OS was investigated using Kaplan-
Meier curves and log rank-test.  No significant associations 
were found between the expression of wtEGFR and 
EGFRvIII and OS in this study.  BTC positivity in >50% 
of tumour cells (P = 0.003) and epigen expression with an 
intensity of 2+ (P = 0.002) were significantly associated 
with poorer OS (Figure 3A). Interestingly, the expression 
of TGFα was found to be significantly associated with a 
better OS (P = 0.020) (Figure 3A). 
Using univariate analysis, we found a 3-fold and 
5-fold increased risk of a shorter OS with expression of 
BTC (P = 0.009) and epigen (P = 0.005) (Table 4). BTC 
(P = 0.023), epigen (P = 0.005), and TGFα (P = 0.016) 
were all found to remain independent prognostic factors 
for survival when analysed using multivariate analysis in 
this study (Table 4).             
Impact of EGFR and EGFR ligands expression 
on progression-free survival 
Interestingly, PFS was significantly shorter in 
patients with wtEGFR expression > 5% positive tumour 
cells (P = 0.000244), which in this study was found to 
be predominantly cytoplasmic (Figures 1 and 3B). In 
addition, using univariate and multivariate analyses we 
found that the expression of wtEGFR (> 5%) increased 
the risk of shorter PFS by nearly 3-fold (P = 0.001) 
and remain an independent predictive biomarker of 
shorter PFS (P = 0.008) (Table 4). The expression of 
amphiregulin was found to be significantly associated 
Figure 1: Immunostaining of wtEGFR and EGFRvIII in mCRC specimens. Immunostaining of wtEGFR, and EGFRvIII 
in formalin fixed paraffin embedded tumour sections stained immunohistochemically, as described under methods and patients section. 
Magnification: x200
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with a shorter PFS (P = 0.004) and increased the risk 
of a shorter PFS by nearly 5-fold (P = 0.018) (Table 4). 
However, in multivariate analysis this association failed to 
reach statistical significance (Table 4).  Interestingly, the 
co-expression of wtEGFR and any one (P = 0.000347) 
or two (P = 0.006) ligands was found to be significantly 
associated with shorter PFS in this study (Table 4, 
Figure 3B). Of these, the co-expression of wtEGFR 
and epigen at cut-off value of >5% was found to be 
significantly associated with shorter PFS (P = 0.013) in 
both univariate (P = 0.022) and multivariate analyses 
(P = 0.025). In addition, the co-expression of wtEGFR 
(> 5%) and BTC (> 50%) was significantly associated 
with shorter PFS (P = 0.000175) (Table 4, Figure 3B). 
In univariate analysis, this association was shown to 
increase the risk of shorter PFS by 4-fold (P = 0.002) and 
remained an independent predictive biomarker of shorter 
PFS (P = 0.014) (Table 4).  Like OS, EGFRvIII was not 
significantly associated to PFS in this study (Data not 
shown).
DISCUSSION
At present mCRC patients are selected for anti-
EGFR mAb therapy provided their tumours do not 
harbour any RAS mutations, as no clear associations have 
yet been found between the expression of EGFR protein 
determined by immunohistochemistry and response to 
these inhibitors [4, 26–28]. A major contributing factor for 
such discordance could be the use of antibodies that do 
not discriminate between the wild-type and mutated forms 
of the EGFR in such patients [13]. Other contributing 
factors could be the use of very low cut-off value of 
EGFR positivity in the earlier studies (i.e. EGFR positivity 
Table 1: Clinicopathological parameters and survival of 60 mCRC patients treated with anti-
EGFR mAb cetuximab
Characteristics Number of patients (%)
OS in years 
(mean ± SE) 95% CI P-value
PFS in 
months
(mean ± SE)
95% CI P-value
Age in years
≤ 70
> 70
44 (73)
16 (27)
4.8 ± 0.5
4.1 ± 0.4
3.2–4.7
3.8–5.6 NS
17.5 ± 4.3
9.2 ± 2.4
9.0–25.9
4.4–14.0 NS
Gender
Male
Female
42 (70)
18 (30)
4.9 ± 0.5
3.9 ± 0.3
3.9–6.0
3.3–4.5 NS
15.6 ± 4.2
13.8 ± 3.9
7.4–23.9
6.2–21.4 NS
Tumour Site
Right colon
Left colon
Liver Resections
11 (18)
29 (48)
14 (23)
3.9 ± 0.0
3.8 ± 0.2
3.7 ± 0.3
3.9–3.9
3.4–4.2
3.0–4.4 NS
7.9 ± 4.4
12.3 ± 2.4
10.6 ± 3.5
0.0–16.5
7.6–16.9
3.8–17.4
NS
T stage*
< T4
T4
16 (27)
23 (38)
3.6 ± 0.2
4.2 ± 0.4
3.2–4.0
3.4–5.0 NS
16.1 ± 3.6
7.4 ± 2.2
8.9–23.1
3.0–11.7 0.014
N Stage*
< N2
N2
18 (30)
21 (35)
3.8 ± 0.3
3.7 ± 0.2
3.3–4.3
3.3–4.2 NS
12.1 ± 3.0
10.7 ± 2.9
6.2–18.0
4.9–16.5 NS
Vascular Invasion*
V0
V1
16 (26)
23 (38)
3.3 ±0.2
4.1 ± 0.2
2.9–3.7
3.6–4.5 0.017
8.3 ± 2.9
13.6 ± 2.8
2.6–14.0
8.0–19.1 NS
Grade*
< G3
G3
29 (48)
10 (16)
3.8 ± 0.2
4.1 ± 0.2
3.4–4.2
3.7–4.4 NS
12.2 ± 2.4
6.6 ± 3.7
7.4–16.9
0.0–14.0 NS
Chemotherapy
Folfiri + Cetuximab
Folfox + Cetuximab
31 (51)
29 (48)
4.8 ± 0.5
4.4 ± 0.5
3.8–5.9
3.4–5.4 NS
11.6 ± 2.8
18.6 ± 5.4
6.0–17.2
8.1–29.2 NS
OS and PFS relative to the indicated features were determined by Kaplan-Meier analysis and the log-rank test. P-value of 
≤ 0.05 was considered significant.
*data for T stage, N stage, Vascular invasion, and grade missing in 21 patients. OS and PFS analysis was conducted by 
omitting the missing data. 
Oncotarget5www.impactjournals.com/oncotarget
when immunostaining is present in ≥1% of tumour cells) 
[29, 30], and discordance between the expression of EGFR 
in the primary tumour and the metastatic sites [31, 32]. 
While the mutational status of KRAS has been a well-
known negative predictor of response to antibody therapy, 
the efficacy of anti-EGFR mAb therapy is modest even 
in some KRAS-wild type mCRC patients, and about 40% 
of patients without KRAS or BRAF mutations also have 
poor response to therapy with anti-EGFR antibodies [33]. 
In addition, objective responses have been detected in 
patients with KRAS-mutated tumours [17, 34]. Indeed, the 
latest American Society of Clinical Oncology provisional 
clinical opinion recommended that patients considered for 
anti-EGFR therapy should be tested for mutations in KRAS 
exons2 (codons 12 and 13), as well as extended  KRAS 
exons 3 (codons 59 and 61) and 4 (codons 117 and 146) 
and NRAS exons 2 (codons 12 and 13), 3 (codons 59 and 
61), and 4 (codons 117 and 146), as patients with such 
mutations are unlikely to benefit from therapy with anti-
EGFR antibodies. While mutation testing to include NRAS 
in mCRC patients may improve the predictive value of 
such “passengers biomarker” for response to anti-EGFR 
mAb therapy, NRAS mutations are extremely rare and 
comprise only 2% of the mCRC patient population [4, 
35]. Consequently, this present study was designed to 
investigate the relative expression and predictive value 
wtEGFR and EGFRvIII proteins and EGFR ligands, using 
specific antibodies in 60 KRAS-wild type mCRC patients 
treated with cetuximab. 
We have shown previously that inconsistencies 
in the use of different cut-off values for EGFR 
immunostaining can be a major contributing factor for 
the variation in the expression and consequently the 
impact on the clinical outcome of anti-EGFR treatment 
in patients [36]. In this study we therefore evaluated the 
expression of EGFR and EGFR ligands using various cut-
off values, as well as the location of the immunostaining 
(Table 2). We found the expression of wtEGFR, at cut-
off value >5% positive tumour cells, to be a predictor of 
poor response to cetuximab, and an independent predictive 
biomarker of shorter PFS in this study. Interestingly, the 
predominant pattern of wtEGFR immunostaining in this 
study was cytoplasmic. Since, the binding site of anti-
EGFR mAb cetuximab is on the extracellular domain of 
the EGFR, it is incapable of binding to the cytoplasmic 
EGFR and inducing the antibody-dependent cell-mediated 
cytotoxicity (ADCC) [37]. As a result, the association 
between cytoplasmic wtEGFR expression and poor 
response to cetuximab observed in our study is plausible. 
Further analysis of our data revealed that up to 40% of the 
tumours used in this study were treated with cetuximab 
prior to their surgical resection and 96% of wtEGFR 
Table 2: Immunohistochemical expression of EGFR and EGFR ligands and their co-expressions in 
60 mCRC patients using the Fisher’s exact test, FET
Variables
No. of positive tumours (%)
% Positive tumour cells Intensity Location
> 5 > 10 > 20 > 50 1+ 2+ 3+ Mem Cyto
wtEGFR 27 (44) 23 (38) 16 (26) 8 (13) 27 (44) 1 (2) 0 7 (12) 27 (44)
EGFRvIII 25 (41) 25 (41) 17 (28) 12 (20) 23 (38) 1 (2) 1 (2) 0 25 (41)
Amphiregulin 21 (34) 16 (27) 7 (12) 5 (8) 18 (30) 3 (5) 0 0 21 (34)
BTC 43 (72) 40 (67) 34 (57) 19 (32) 18 (30) 29 (48) 1 (2) 0 43 (72)
EGF 19 (31) 17 (28) 12 (20) 7 (12) 20 (33) 1 (2) 0 0 19 (31)
Epigen 41 (67) 33 (54) 25 (41) 17 (28) 33 (54) 9 (15) 1 (2) 0 40 (66)
TGFα 35 (58) 33 (55) 30 (50) 26 (43) 31 (52) 11 (18) 0 0 35 (58)
wtEGFR/Amph 13 (22) 11 (18) 3 (5) 2 (3) 10 (17) 0 0 - -
wtEGFR/BTC 18 (30) 13 (22) 8 (13) 2 (3) 6 (10) 0 0 - -
wtEGFR/EGF 6 (10) 4 (7) 3 (5) 0 8 (13) 0 0 - -
wtEGFR/Epigen 17 (28) 11 (18) 6 (10) 1 (2) 12 (20) 0 0 - -
wtEGFR/TGFα 16 (27) 12 (20) 8 (13) 3 (5) 13 (22) 1 (2) 0 - -
wtEGFR/1 ligand 26 (43) 22 (37) 15 (25) 7 (12) 24 (40) 1(2) 0 - -
wtEGFR/ 2 ligands 21 (35) 17 (28) 8 (13) 6 (10) 16 (27) 0 0 - -
wtEGFR/ 3 ligands 14 (23) 10 (17) 4 (7) 0 8 (13) 0 0 - -
wtEGFR/ 4 ligands 9 (15) 2 (3) 0 0 1 (2) 0 0 - -
Mem, Membranous; Cyt, Cytoplasmic
P-value of ≤ 0.05 was considered significant
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positive cases co-expressed at least one EGFR ligand. 
One of the known mechanisms of action of cetuximab is 
downregulation of the EGFR by binding to the receptor 
and resulting in its internalisation. In addition, few 
preclinical data in other cancer models have reported 
that binding of EGFR ligands can also accelerate EGFR 
internalisation and as such elevate its localisation in the 
cytoplasm [38, 39]. It is therefore plausible that treatment 
with cetuximab and the abundant expression of one or 
more EGFR ligand could in fact have contributed to the 
downregulation of the EGFR from the cell surface to the 
cytoplasm in this study. 
The relatively common expression of EGFRvIII 
(41%) was surprising but also an important finding in 
this study. Interestingly, in one patient we observed that 
while there was no detectable expression of EGFR in 
the primary tumour, the liver metastasis from the same 
patient was strongly positive for EGFRvIII expression 
(Data not shown). Arguably, while this observation was 
seen in only one patient, nevertheless it highlights an 
important fact that EGFR expression can alter between 
the primary site and distant metastatic lesions [31] and 
such mutations could contribute to secondary resistance 
to  anti-EGFR mAbs therapy [40–42]. In addition, 
several clinical trials for vaccines targeting EGFRvIII 
in glioblastoma are currently underway [43]. In the first 
phase III immunotherapy trial (ACT IV study) with 
Rintega (rindopepimut) cancer vaccine, consisting of the 
unique 14 mer EGFRvIII peptide sequence conjugated 
to keyhole limpet hemocyanin, the unexpected strong 
performance of the control arm lead to the termination of 
this study although there are a subset of patients on the 
Rintega arm who did very well long term. It is currently 
unclear which factors lead to better performance in these 
patients. However, the high level of EGFRvIII reported in 
this study for patients with colorectal cancer suggest that 
Figure 2: Immunostaining of EGFR ligands and co-expression with wtEGFR in mCRC specimens. Expression of 
Amphiregulin, BTC, EGF, Epigen, and TGFα (A), and co-expression of wtEGFR, Amphiregulin, BTC, EGF, epigen, and TGFα in a 
particular patient (B) in formalin fixed paraffin embedded tumour sections stained immunohistochemically as described under methods and 
patients section. Magnification: x200
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Table 3: The association of wtEGFR and EGFR ligands at cut-off value of > 5% positive 
immunostaining with response to treatment with cetuximab and disease progression in 60 mCRC 
patients using the Fisher’s exact test, FET
Variables
Association with:
Response to cetuximab
Yes No P-value
wtEGFR
+ve 16 11 0.026
–ve 28 5
wtEGFR/1 ligand
+ve 15 11 0.021
–ve 29 5
wtEGFR/1 ligand§
+ve 11 11 0.005
–ve 33 5
wtEGFR/BTC§
+ve 5 8 0.003
–ve 39 8
wtEGFR/BTC†
+ve 3 5 0.026
–ve 41 11
wtEGFR/TGFα§
+ve 5 7 0.01
–ve 39 9
Disease Progression
Yes No P-value
wtEGFR
+ve 26 1 0.002
–ve 20 13
Amphiregulin§
+ve 16 0 0.013
–ve 30 14
BTC
+ve 29 14 0.006
–ve 17 0
EGF*
+ve 3 4 0.045
–ve 43 10
Epigen/BTC
+ve 20 11 0.032
–ve 26 3
wtEGFR/Amph
+ve 13 0 0.027
–ve 33 14
wtEGFR/BTC
+ve 17 1 0.045
–ve 29 13
wtEGFR/Epigen
+ve 16 1 0.05
–ve 30 13
wtEGFR/TGFα
+ve 16 0 0.013
–ve 30 14
wtEGFR/1 ligand
+ve 25 1 0.002
–ve 21 13
wtEGFR/ 2 ligands
+ve 20 1 0.022
–ve 26 13
wtEGFR/ 3 ligands
+ve 14 0 0.026
–ve 32 14
§, at cut-off value of  > 10%; †, at cut-off value of  > 20%; *, at cut-off value of > 50%
P-value of  ≤ 0.05 was considered significant.
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Table 4: Univariate and multivariate analysis related to OS and PFS in 60 mCRC treated with 
anti-EGFR mAb cetuximab
Variables Overall Survival (OS)
Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Vascular Invasion 0.201 0.048–0.834 0.027 0.204 0.049–0.852 0.029
BTC† 3.228 1.337–7.791 0.009 4.463 1.235–16.133 0.023
Epigen (2+) 4.867 1.610–14.707 0.005 11.533 2.092–63.569 0.005
TGFα (>20%) 0.368 0.153–0.887 0.026 0.073 0.009–0.612 0.016
Progression-free Survival (PFS)
Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Tumour Stage 0.442 0.202–0.966 0.041 0.351 0.146–0.844 0.019
wtEGFR (> 5%) 2.752 1.519–4.989 0.001 2.829 1.316–6.079 0.008
Amphiregulin (2+) 4.554 1.301–15.936 0.018 - - NS
wtEGFR/1 ligand 2.673 1.480–4.826 0.001 2.717 1.274–5.792 0.010
wtEGFR/2 ligands 2.141 1.187–3.862 0.011 2.306 1.093–4.862 0.028
wtEGFR/Epigen* 2.063 1.111–3.831 0.022 2.450 1.119–5.364 0.025
wtEGFR/BTC** 4.136 1.701–10.056 0.002 3.814 1.315–11.060 0.014
HR, hazard ratio; CI, confidence interval; †, cut-off value > 50% used for OS and PFS; *, cut-off value of > 5% used; **, 
cut-off value of > 5% (wtEGFR) and > 50% (BTC); NS, Not significant
P-value of ≤ 0.05 was considered significant
Figure 3: The association between wtEGFR and EGFR ligands and OS and PFS in mCRC patients treated with 
cetuximab. Kaplan-Meier survival curves showing the impact on the OS of the patients with BTC, TGFα, and Epigen, expression (A), 
PFS with wtEGFR, co-expressions of wtEGFR and BTC, and wtEGFR and 1 ligand (B). A log-rank test value of P ≤  0.05 was considered 
statistical significance.
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such patients should also be included in future studies with 
EGFRvIII targeting vaccine. 
Several studies have examined the mRNA 
expression levels of EGFR ligands and have found an 
association between the expression level of epiregulin, 
amphiregulin and TGFα and response to treatment 
with cetuximab [3, 18, 19, 24, 44, 45]. However, the 
increased expressed level of these genes may not always 
be translated into the corresponding proteins, which are 
directly competing with antibodies to bind on the EGFR 
on tumour cells.  To our knowledge, there has only been 
one study investigating the predictive value of all EGFR 
ligand proteins.  Yoshida and colleagues determined the 
expression level of EGFR ligand proteins in 26 mCRC 
patients with KRAS wild-type treated with anti-EGFR 
mAbs cetuximab or panitumumab. They found that co-
expression of four EGFR ligands, at cut-off value of 
>30%, (amphiregulin, HB-EGF, TGFα, and epiregulin) 
might be a novel predictive biomarker of higher response 
rate to cetuximab and panitumumab therapy [46]. By 
contrast, we found the expressions of BTC and epigen to 
be significantly associated with a poorer OS. Since BTC 
is one of the most commonly expressed ligands in the 
gastrointestinal tract [47, 48] this could in part explain the 
high proportion of samples (72%) expressing BTC at a 
cut-off value >5%. We therefore analysed the impact of 
BTC expression at a cut-off value of more than 50% of 
the positive tumour cells on OS to minimise the effect 
of low specific expression of BTC. To our knowledge 
the association of the co-expression of wtEGFR and its 
ligands with clinical outcome has not been previously 
reported. Of note, we found the co-expressions of wtEGFR 
and any one ligand and in particular BTC and TGFα to be 
associated with poorer response to cetuximab and a shorter 
PFS. Indeed, analyses of the co-expression of wtEGFR 
and ligands higher cut-off values of >10% and >20% 
yielded much stronger associations with poorer response 
to cetuximab in this study.  The abundant expression of 
EGFR ligands such as BTC and TGFα can result in the 
downregulation of the cell surface EGFR, impeding the 
binding ability of cetuximab, which could explain the 
associations with poorer response to cetuximab and shorter 
PFS in this study. Indeed, other studies also suggest that 
the cellular location of the EGFR not only can influence 
response to therapeutics but could also play an important 
role in cancer progression and patients’ survival [3, 49]. 
With the recent FDA approval of another anti-
EGFR mAb, necitumumab [50], the undisputable fact 
remains that EGFR is an important therapeutic target for 
therapy with anti-EGFR mAbs, as well as small molecule 
tyrosine kinase inhibitors, albeit an expensive one. To our 
knowledge, the predictive value of wtEGFR in terms of 
its cytoplasmic location and its competing ligands and 
association with a shorter PFS in mCRC patients has not 
been previously reported. While the presence of KRAS and 
NRAS mutations could aid in the sparing of patients with 
primary resistance to treatment with anti-EGFR mAbs, it 
is vital to determine the relative expression and cellular 
location of EGFR protein (i.e. the therapeutic target) and 
its competing ligand proteins in patients with wild-type 
KRAS and NRAS prior to therapy anti-EGFR mAbs. Taken 
together, these could aid in the selection of a more specific 
population of mCRC patients who are more likely to gain 
long term benefit from therapy with anti-EGFR antibodies, 
and would spare other patients from receiving the 
ineffective and expensive treatment, with the associated 
toxicities.
Finally, in a significant number of cases, the 
patient has previously received post-operative adjuvant 
chemotherapy, before developing metastases and being 
considered for second time chemotherapy. Currently, most 
patients undergo a single assessment of their cancer’s RAS 
status. This is often performed on a small colorectal biopsy 
or on a larger resection specimen of the colon or rectum, 
which can often pre-date the metastases by a couple of 
years. Less frequently, RAS assessment is performed on 
a recent biopsy of a metastasis or the completely resected 
metastatic lesion - more commonly from the lung or 
liver. In the former situation, the decision about using 
cetuximab can be based on the molecular profile of a 
tumour sample which may or may not be the same as that 
of the metastases, as seen in this study. This question of 
when, and from which specimen, the RAS test should be 
performed is something that needs further investigation, as 
currently it is an ad hoc process in most laboratories. As a 
result, large prospective randomised investigation will be 
vital for the validation of these findings and could lead to 
more effective targeted therapy of patients with anti-EGFR 
antibodies.   
MATERIALS AND METHODS
Ethical approval was obtained from the Research 
and Development Committee of the Royal Surrey County 
Hospital for examination of 60 mCRC surgically resected 
(R0) primary tumour and liver metastatic specimens 
from patients treated with post-operative adjuvant 
chemotherapy, FOLFOX or FOLFIRI plus cetuximab 
between May 2008 and January 2014 for use in this 
retrospective study. Official reports, radiographic studies, 
including follow up computed tomography scans were 
reviewed to evaluate response to cetuximab therapy using 
the RECIST criteria v1.1 [51].
Immunohistochemistry
IHC staining was carried out as described previously 
[36], using the following primary antibodies: mouse 
anti-wild-type EGFR (M7298) and mouse anti-phospho-
EGFR (Tyr 1173) (M7299)  (Dako, UK), anti-EGFRvIII 
(BS-2558R, Bioss, USA), rabbit pAb anti-Amphiregulin 
(GTX100986, GeneTex, USA) rabbit anti-phospho-EGFR 
Oncotarget10www.impactjournals.com/oncotarget
(Tyr 1068) (2234, New England Biolabs, UK), mouse 
anti-EGF (AHP767), mouse anti-TGFα (AHP284G) (Abd 
Serotec, UK), mouse anti-Betacellulin (MAB2611) (R&D 
Systems, UK), rabbit pAb anti-HBEGF (HPA053243), 
rabbit pAb anti-Epigen (HPA014420), and rabbit pAb 
anti-Epiregulin (HPA054373) (Sigma, UK). 
Scoring criteria
The immunostaining of the tumour sections 
were scored as described previously [36]. Briefly, the 
immunostaining of the tumour sections were scored 
based on the percentage of tumour cells that had HER 
immunostaining (i.e. > 5%, > 10%, > 20%, and > 50%) 
and intensity of immunostaining (i.e. negative 0, weak 1+, 
moderate 2+ and strong 3+) and location (i.e. membrane, 
cytoplasm or nucleus of the cells). Two independent 
observers (including a consultant histopathologist), 
blinded to all clinical information, conducted the scoring 
and any disparity in scoring was resolved by simultaneous 
reassessment of the staining by both observers.  
Statistical analysis
Statistical analysis was carried out in PASW 
statistics 22 (SPPS Inc.) using Chi-square or Fishers’ exact 
test (where expected counts were less than 5), Kaplan-
Meier survival plots and log rank-test and Cox survival 
regression model. P ≤ 0.05 was considered statistically 
significant. 
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